Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK117 + azacitidine
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
AK117 + azacitidine is an investigational combination therapy comprising AK117 (ligufalimab), a next-generation humanized IgG4 anti-CD47 monoclonal antibody, and azacitidine, a hypomethylating agent. AK117 blocks the CD47-SIRPα interaction, thereby promoting phagocytic activity of immune cells against tumor cells. Azacitidine inhibits DNA methylation, interfering with cancer cell growth. This combination is being evaluated in phase 2 clinical trials for the treatment of newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS), aiming to improve remission rates and address unmet needs in this patient population. AK117 is developed by Akeso, which also manufactures the product[1][2][3][7].
- Other names
- ligufalimab + azacitidine
02
Targets
CD47 (Cluster of Differentiation 47)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on AK117 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK117 + azacitidine.